Equities

Aarey Drugs and Pharmaceuticals Ltd

AAREYDRUGS:NSI

Aarey Drugs and Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)67.30
  • Today's Change0.96 / 1.45%
  • Shares traded46.04k
  • 1 Year change+41.68%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 11:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments291177
Total Receivables, Net2,0001,9951,363
Total Inventory347652137
Prepaid expenses--25--
Other current assets, total45023686
Total current assets2,8262,7062,263
Property, plant & equipment, net130139145
Goodwill, net------
Intangibles, net------
Long term investments144.084.00
Note receivable - long term7.057.7840
Other long term assets5756--
Total assets3,0332,9132,452
LIABILITIES
Accounts payable1,2891,2731,097
Accrued expenses--(291)--
Notes payable/short-term debt00142
Current portion long-term debt/capital leases281334--
Other current liabilities, total9536663
Total current liabilities1,6651,6811,301
Total long term debt32440
Total debt314377142
Deferred income tax7.491415
Minority interest------
Other liabilities, total--0.000
Total liabilities1,7051,7391,315
SHAREHOLDERS EQUITY
Common stock281254254
Additional paid-in capital25411--
Retained earnings (accumulated deficit)1,023509883
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity1,3281,1741,136
Total liabilities & shareholders' equity3,0332,9132,452
Total common shares outstanding282525
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.